Background: Patients with rheumatoid arthritis (RA) treated with Janus kinase inhibitors (JAKi) have an increased risk of herpes zoster (HZ). A non‑live, recombinant subunit vaccine (Shingrix) offers protection in adults aged ≥50 years, but its effectiveness in RA patients receiving JAKi is unclear. Objective: To determine whether vaccination with Shingrix reduces HZ incidence in RA patients treated with JAKi compared with unvaccinated matched RA controls. Methods: Eighty‑eight RA patients on JAKi therapy at Skåne University Hospital received two doses of Shingrix two months apart. For each vaccinated patient, four RA controls matched for age, sex and diagnosis were identified from a regional healthcare registry and assumed to be unvaccinated due to limited vaccine availability. Herpes zoster infections occurring five years before and up to four years after vaccination were retrieved from registry data. Incidence rates (IRs) per 1,000 person‑years were calculated before and after vaccination. Results: RA patients treated with JAKi had a significantly higher incidence of HZ compared with matched RA controls. The IR among vaccinated patients remained at approximately the same level after vaccination. Conclusion: Despite limited follow‑up and few events, the study suggests that the recombinant HZ vaccine provides protection in RA patients receiving JAKi, though vaccinated patients continue to experience higher incidence than controls【676716603728099†L164-L191】.